IL-6 and ovarian cancer: inflammatory cytokines in promotion of metastasis.
- Published in:
- Cancer Management & Research, 2018, v. 10, p. 6685, doi. 10.2147/CMAR.S179189
- By:
- Publication type:
- Article
Works matching AstraZeneca PLC
Results: 988
1
2
An evaluation of treatment options for lateral epicondylitis.
- Published in:
- Journal of Surgery & Medicine (JOSAM), 2020, v. 4, n. 12, p. 1182, doi. 10.28982/josam.755934
- By:
- Publication type:
- Article
3
AstraZeneca and Breast Cancer Advocacy: Why is advocacy a good idea for business and for cancer associations, and how does such an alliance work for mutual benefit?
- Published in:
- Breast Disease, 1998, v. 10, n. 5/6, p. 65, doi. 10.3233/BD-1998-105-610
- By:
- Publication type:
- Article
4
Anastrozole Gains Full Approval for Adjuvant Treatment of Early Breast Cancer.
- Published in:
- Oncology (08909091), 2005, v. 19, n. 11, p. 1
- Publication type:
- Article
5
ZD6 74 Headed for Phase III Trials in the Fall.
- Published in:
- Oncology (08909091), 2005, v. 19, n. 9, p. 1140
- Publication type:
- Article
6
Gefitinib Gets US Label Change and New Distribution Program.
- Published in:
- Oncology (08909091), 2005, v. 19, n. 8, p. 1072
- Publication type:
- Article
7
EU Financial accounts reports.
- Published in:
- Journal of Commercial Biotechnology, 2002, v. 8, n. 4, p. 355, doi. 10.5912/jcb453
- By:
- Publication type:
- Article
8
ETHICAL PRODUCTS.
- Published in:
- 2012
- Publication type:
- Product Review
9
New approved use for Crestor.
- Published in:
- Australian Journal of Pharmacy, 2011, v. 92, n. 1093, p. 44
- Publication type:
- Article
10
AstraZeneca and Galderma enter into R&D collaboration.
- Published in:
- Australian Journal of Pharmacy, 2011, v. 92, n. 1091, p. 66
- Publication type:
- Article
11
Emphasise 'good' cholesterol benefits.
- Published in:
- Australian Journal of Pharmacy, 2010, v. 91, n. 1078, p. 24
- Publication type:
- Article
12
Kinesin inhibitor marches toward first-in-class pivotal trial.
- Published in:
- Nature Medicine, 2013, v. 19, n. 12, p. 1550, doi. 10.1038/nm1213-1550a
- By:
- Publication type:
- Article
13
Drug companies hope to breathe life into asthma pipeline.
- Published in:
- Nature Medicine, 2011, v. 17, n. 6, p. 642, doi. 10.1038/nm0611-642b
- By:
- Publication type:
- Article
14
Clinical drive prompts pharma and academia to partner up.
- Published in:
- Nature Medicine, 2011, v. 17, n. 1, p. 3, doi. 10.1038/nm0111-3
- By:
- Publication type:
- Article
15
From the sponsors.
- Published in:
- Nature Medicine, 2002, v. 8, n. 11, p. 1208, doi. 10.1038/nm1102-1208
- By:
- Publication type:
- Article
16
Adrenaline 0.5%?
- Published in:
- Anaesthesia, 2001, v. 56, n. 8, p. 799, doi. 10.1046/j.1365-2044.2001.02181-31.x
- By:
- Publication type:
- Article
17
A reply.
- Published in:
- Anaesthesia, 2001, v. 56, n. 8, p. 799, doi. 10.1046/j.1365-2044.2001.02181-32.x
- By:
- Publication type:
- Article
18
A reply.
- Published in:
- Anaesthesia, 2000, v. 55, n. 6, p. 609, doi. 10.1046/j.1365-2044.2000.01479-32.x
- By:
- Publication type:
- Article
19
Impact of patent expiry on the top five pharmaceutical companies.
- Published in:
- Journal of Generic Medicines, 2004, v. 1, n. 4, p. 381, doi. 10.1057/palgrave.jgm.4940045
- Publication type:
- Article
20
Banking on share buybacks.
- Published in:
- Chemistry & Industry, 2011, n. 15, p. 12
- By:
- Publication type:
- Article
21
Science briefs.
- Published in:
- Chemistry & Industry, 2009, n. 13, p. 10
- Publication type:
- Article
22
Science briefs.
- Published in:
- Chemistry & Industry, 2009, n. 2, p. 9
- Publication type:
- Article
23
Step change for retrosynthetic analysis.
- Published in:
- Chemistry & Industry, 2009, n. 1, p. 6
- By:
- Publication type:
- Article
24
Business digest.
- Published in:
- Chemistry & Industry, 2008, n. 23, p. 13
- Publication type:
- Article
25
FDA sends 23 warning letters about drug ads.
- Published in:
- Chemistry & Industry, 2005, n. 3, p. 6
- By:
- Publication type:
- Article
26
The COPD Pipeline XII.
- Published in:
- COPD: Journal of Chronic Obstructive Pulmonary Disease, 2011, v. 8, n. 5, p. 387, doi. 10.3109/15412555.2011.613704
- By:
- Publication type:
- Article
27
Partnership Creation to Boost Participation.
- Published in:
- Applied Clinical Trials, 2007, v. 16, n. 8, p. 22
- By:
- Publication type:
- Article
28
CLINICAL TRIALS NEWS.
- Published in:
- Applied Clinical Trials, 2007, v. 16, n. 2, p. 16
- Publication type:
- Article
29
Clinical Trials News.
- Published in:
- Applied Clinical Trials, 2005, v. 14, n. 2, p. 18
- Publication type:
- Article
30
Other news.
- Published in:
- Applied Clinical Trials, 2005, v. 14, n. 1, p. 21
- Publication type:
- Article
31
Journal of Diabetes News.
- Published in:
- Journal of Diabetes, 2014, v. 6, n. 4, p. 274, doi. 10.1111/1753-0407.12145
- Publication type:
- Article
32
Department of Health and Human Services, AstraZeneca to Develop Antibiotics.
- Published in:
- Clinical Infectious Diseases, 2015, v. 61, n. 11, p. i, doi. 10.1093/cid/civ889
- By:
- Publication type:
- Article
33
FDA PANEL OKs NEWER ANTIPSYCHOTICS FOR CHILDREN.
- Published in:
- Psychiatry (1550-5952), 2009, v. 6, n. 6, p. 12
- Publication type:
- Article
34
ASTRAZENECA RECEIVES FDA COMPLETE RESPONSE LETTER ON SEROQUEL XR FOR GENERALIZED ANXIETY DISORDER.
- Published in:
- Psychiatry (1550-5952), 2009, v. 6, n. 3, p. 12
- Publication type:
- Article
35
INTEREST trial shows gefitinib to be as effective as docetaxel for the treatment of non-small-cell lung cancer.
- Published in:
- 2009
- Publication type:
- Product Review
36
Ceftaroline fosamil.
- Published in:
- Australian Prescriber, 2013, v. 36, n. 3, p. 105
- Publication type:
- Article
37
Ticagrelor.
- Published in:
- Australian Prescriber, 2011, v. 34, n. 5, p. 158
- Publication type:
- Article
38
Court clears the way for Nexium alternative.
- Published in:
- Nature Reviews Drug Discovery, 2014, v. 13, n. 2, p. 94, doi. 10.1038/nrd4240
- By:
- Publication type:
- Article
39
Deal watch: AstraZeneca bets on FibroGen's anaemia drug.
- Published in:
- Nature Reviews Drug Discovery, 2013, v. 12, n. 10, p. 730, doi. 10.1038/nrd4135
- By:
- Publication type:
- Article
40
Integrin inhibitors go with the gut.
- Published in:
- Nature Reviews Drug Discovery, 2013, v. 12, n. 6, p. 411, doi. 10.1038/nrd4037
- By:
- Publication type:
- Article
41
Menelas Pangalos.
- Published in:
- Nature Reviews Drug Discovery, 2013, v. 12, n. 6, p. 418, doi. 10.1038/nrd4044
- By:
- Publication type:
- Article
42
European Lead Factory opens for business.
- Published in:
- Nature Reviews Drug Discovery, 2013, v. 12, n. 3, p. 173, doi. 10.1038/nrd3956
- By:
- Publication type:
- Article
43
Patent watch.
- Published in:
- Nature Reviews Drug Discovery, 2013, v. 12, n. 2, p. 94, doi. 10.1038/nrd3948
- By:
- Publication type:
- Article
44
News in brief.
- Published in:
- Nature Reviews Drug Discovery, 2012, v. 11, n. 10, p. 739, doi. 10.1038/nrd3865
- Publication type:
- Article
45
News in brief.
- Published in:
- Nature Reviews Drug Discovery, 2012, v. 11, n. 9, p. 663, doi. 10.1038/nrd3840
- Publication type:
- Article
46
Patent watch.
- Published in:
- Nature Reviews Drug Discovery, 2012, v. 11, n. 5, p. 344, doi. 10.1038/nrd3735
- By:
- Publication type:
- Article
47
Market watch: Upcoming market catalysts in Q4 2011.
- Published in:
- Nature Reviews Drug Discovery, 2011, v. 10, n. 10, p. 723, doi. 10.1038/nrd3564
- By:
- Publication type:
- Article
48
Diabetes field cautiously upbeat despite possible setback for leading SGLT2 inhibitor.
- Published in:
- Nature Reviews Drug Discovery, 2011, v. 10, n. 9, p. 645, doi. 10.1038/nrd3546
- By:
- Publication type:
- Article
49
News in brief.
- Published in:
- Nature Reviews Drug Discovery, 2011, v. 10, n. 4, p. 247, doi. 10.1038/nrd3421
- Publication type:
- Article
50
News in brief.
- Published in:
- Nature Reviews Drug Discovery, 2011, v. 10, n. 3, p. 165, doi. 10.1038/nrd3409
- Publication type:
- Article